HIV-prevention drug to launch in 2027, priced at $40 annually  Generic versions of a groundbreaking injectable HIV-prevention drug should be available for $40 a year in more than 100 countries from 2027, Unitaid and the Gates Foundation said Wednesday. The two organisations have entered into separate agreements with Indian pharmaceutical companies to produce cheaper generic versions of lenacapavir — a twice-yearly injection shown to reduce the risk of HIV transmission by more than 99.9 per cent — for low and middle-income countries. Marketed under the brand name Yeztugo by California-based Gilead Sciences,...